## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPE	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

e Response	s)													
Name and Address of Reporting Person * 2. Iss				2. Issuer Fund Tiener of Truding Symbol						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
) GH BLUI	(First) FF DR., SUITE 2					e title below)	Oth	er (specify belo	w)					
150 G. 1	(Street)		_X_1			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person								
GO, CA 9	92130 (State)	(Zip)			т	abla I	Non Dori	vativa Saguritia	os A aquirad	Disposed	of or Dono	ficially Own	ad	
ecurity		2. Transaction Date (Month/Day/Year)	Execut	ion I	d Date, if	3. Tra Code (Instr.	nsaction 4 (28) (1	Securities Acq A) or Disposed onstr. 3, 4 and 5)	uired of (D) Ow Tra	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		eneficially d	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Table II -					uired, Dispo	osed of, or Bene	eficially Ow		number.			
2. 3. Transaction Date Secution Date, if Code (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4,			7. Title an of Underly Securities	Title and Amount Underlying ecurities		Derivative Securities Beneficially Owned Following Reported	Ownersl Form of Derivati Security Direct (I or Indire	ve Ownersh (Instr. 4)				
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
			Code											
	GO, CA S  Conversion	AN ROBERT  (First) GH BLUFF DR., SUITE 2 (Street)  GO, CA 92130  (State)  Ecurity  Report on a separate line for each  Conversion or Exercise Price of Derivative	AN ROBERT  () (First) (Middle) GH BLUFF DR., SUITE 200  (Street)  GO, CA 92130  (State) (Zip)  Ecurity  2. Transaction Date (Month/Day/Year)  Table II -  2. Conversion Or Exercise Price of Derivative  A. Deemed Execution Date, if any (Month/Day/Year)	AN ROBERT  DelMa  3. Date of O6/26/2  (Street)  4. If Am  GO, CA 92130  (State)  2. Transaction Date (Month/Day/Year)  Report on a separate line for each class of securities beneficial any (Month/Day/Year)  Table II - Derivate (e.g., pu any (Month/Day/Year))  AN ROBERT  3. DelMa  3. Date of O6/26/2  4. If Am  2. Transaction Date (e.g., pu any (Month/Day/Year))  AN Deemed Execution Date, if Transaction Date (Month/Day/Year)  Code (Instr. 8)	AN ROBERT  DelMar Ph  (Middle)  3. Date of Ea  06/26/2020  (Street)  4. If Amendr  GO, CA 92130  (State)  2. Transaction Date (Month/Day/Year)  Report on a separate line for each class of securities beneficially of Execution Date (Conversion of Execution Date (Month/Day/Year)  3. Transaction Date (Eg., puts, c) (Eg., puts, c) (Month/Day/Year)  A. Deemed Execution Date (Eg., puts, c) (Month/Day/Year)  (Month/Day/Year)	AN ROBERT  DelMar Pharmac  3. Date of Earliest Tr 06/26/2020  (Street)  4. If Amendment, Da  GO, CA 92130  Currity  2. Transaction Date (Month/Day/Year)  Report on a separate line for each class of securities beneficially owned di  Table II - Derivative Securities  (e.g., puts, calls, wa  2. Conversion Oate (Month/Day/Year)  3. Deemed Execution Date, if any (Month/Day/Year)  Table II - Derivative Securities (e.g., puts, calls, wa  2. Conversion Oate (Month/Day/Year)  (Month/Day/Year)  A Code Security  Gode (Instr. 8)	AN ROBERT  DelMar Pharmaceutic.  (Middle)  3. Date of Earliest Transact 06/26/2020  4. If Amendment, Date Original State (Month/Day/Year)  Code (Instr. a)  Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, 4, and and acquired (A) or Disposed of (D) (Instr. 3, 4, 4, and acquired (A) or Disposed of (D) (Instr. 3, 4, 4, and acquired (A) or Disposed of (D) (Instr. 3, 4, 4, and acquired (A) or Disposed of (D) (Instr. 3, 4, 4, and acquired (A) or Disposed of (D) (Instr. 3, 4, 4, and acquired (A) or Disposed of (D) (Instr. 3, 4, 4, and acquired (A) or Disposed of (D) (Instr. 3, 4, 4, and acquired (A) or Disposed of (D) (Instr. 3, 4, 4, and acquired (A) or Disposed of (D) (Instr. 3, 4, 4, and acquired (A) or Disposed of (D) (Instr. 3, 4, and acquired (A) or Disposed of (D) (Instr. 3, 4, and acquired (A) or Disposed of (D) (Instr. 3, 4, and acquired (A) or Disposed of (D) (Instr. 3, 4, and acquired (A) or Disposed of (D) (Instr. 3, 4, and acquired (A) (Instr. 4) (Instr. 4	AN ROBERT  DelMar Pharmaceuticals, Inc. [Date of Earliest Transaction (Month/Inc.)]  (Street)  (A. If Amendment, Date Original Filed(Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Instr. 8)  (Instr. 8)	AN ROBERT  O (First) (Middle)	DelMar Pharmaceuticals, Inc. [DMPI]  3. Date of Earliest Transaction (Month/Day/Year)  06/26/2020  4. If Amendment, Date Original Filed(Month/Day/Year)  GO, CA 92130  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  3. Transaction (Instr. 8)  4. Securities Acquired (A) or Disposed of (D) (Instr. 8)  Persons who respond to the c in this form are not required to displays a currently valid OME  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owe.g., puts, calls, warrants, options, convertible securities)  2. Transaction One Exercise (Month/Day/Year)  2. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owe.g., puts, calls, warrants, options, convertible securities)  2. Transaction One Exercise (Month/Day/Year)  (Month/Day/Year)  3. Transaction Code V Amount (D) Price  Persons who respond to the c in this form are not required to displays a currently valid OME  Table II - Derivative Securities Acquired, One Date (Month/Day/Year)  2. Transaction One Exercise (Month/Day/Year)  (Month/Day/Year)  3. Transaction One Code V Amount (D) Price  Persons who respond to the Code in this form are not required to displays a currently valid OME  Table II - Derivative Securities Acquired, One Date (Month/Day/Year)  (Instr. 3)  A Deemed Execution Date (Month/Day/Year)  A Date E	DelMar Pharmaceuticals, Inc. [DMPI]  (First) (Middle) (GH BLUFF DR., SUITE 200  (Street)  (Street)  (State)  (State)  (State)  (Zip)  (Zip)  (State)  (Zip)  (A) Deemed Execution Date (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (A) or Disposed of, or Beneficially Owned displays a currently valid OMB control of Date (C.g., puts, calls, warrants, options, convertible securities)  (Month/Day/Year)  (	DelMar Pharmaceuticals, Inc. [DMPI]  (First) (	DelMar Pharmaceuticals, Inc. [DMPI]  (Check all applicab (Check al	DelMar Pharmaceuticals, Inc. [DMP1]   X_Director   Office (give title below)   Offic

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
HOFFMAN ROBERT 12707 HIGH BLUFF DR., SUITE 200 SAN DIEGO, CA 92130	X						

### **Signatures**

/s/ Anthony Scott Praill, attorney-in-fact for Robert Hoffman	06/30/2020	
**Signature of Reporting Person	Date	

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for (1) issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020.
- (2) The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.